Neumora Therapeutics (NMRA) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 24.3% versus a loss of 75.3%. OnKure Therapeutics is the larger company by market cap ($93.1 million vs $90.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMRA | OKUR |
|---|---|---|
| Share price | $0.4798 | $2.30 |
| Market cap | $90.15M | $93.14M |
| 1-day change | +2.46% | -2.13% |
| YTD return | -73.20% | -20.69% |
| 1-year return | -75.27% | -24.34% |
| 5-year return | — | -96.43% |
| EPS (TTM) | $-1.23 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.65 | $5.38 |
| 52-week low | $0.45 | $2.13 |
| Distance from 52-week high | -86.85% | -57.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +1179.70% | +573.91% |
| Average volume | 1.19M | 216.96K |
| Shares outstanding | 187.90M | 40.50M |
| Employees | 63 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed NMRA by 50.9 percentage points over the past year.
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
NMRA vs OKUR FAQ
Which is bigger, Neumora Therapeutics or OnKure Therapeutics?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $93.14M compared with $90.15M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, NMRA or OKUR?
OKUR returned -24.34% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Neumora Therapeutics and OnKure Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Neumora Therapeutics and Biotechnology: Pharmaceutical Preparations for OnKure Therapeutics.